Showing results (11-20 of 346) with videos related to
Sort By:
Pageof 35
Expert Opinion on Biological Therapy|July 11, 2008
Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumorsD Ross CamidgeClinical Advances in Hematology & Oncology : H&O|February 13, 2015
Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignoreD Ross CamidgeClinical Lung Cancer|August 8, 2007
The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancerD Ross CamidgeLung Cancer (Amsterdam, Netherlands)|May 3, 2016
Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene statusTejas Patil, Dara L Aisner, Sinead A Noonan, et al.Cancer|January 28, 2012
Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancerD Ross Camidge, Mariana Theodoro, Delee A Maxson, et al.Frontiers in Oncology|May 1, 2020
Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung CancerTejas Patil, Jose M Pacheco, Anastasios Dimou, et al.Cancer|April 11, 2012
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancerAndrew J Weickhardt, Micol S Rothman, Smita Salian-Mehta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2010
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatmentD Ross Camidge, Scott A Kono, Antonella Flacco, et al.Clinical Lung Cancer|August 13, 2013
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerEamon M Berge, Xian Lu, Delee Maxson, et al.Pageof 35